A Phase 1 Open Label/ Phase 2 Randomized, Double-Blind, Multicenter Study Investigating the Combination of RAD001 and Sorafenib (Nexavar) in Patients With Advanced Hepatocellular Carcinoma.
Phase of Trial: Phase I/II
Latest Information Update: 04 Jun 2013
At a glance
- Drugs Everolimus (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Biomarker; Pharmacokinetics; Therapeutic Use
- 09 Apr 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 28 Apr 2012 Additional trial location (Germany) identified as reported by EudraCT.
- 31 Oct 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.